Search Result

Results for "

RAF

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Raf (118) Apoptosis (22) Atg8/LC3 (2) Aurora Kinase (1) Autophagy (25) Bcl-2 Family (1) Bcr-Abl (3) Beta-secretase (2) c-Fms (2) c-Kit (7) c-Met/HGFR (1) Caspase (1) CDK (2) Cholinesterase (ChE) (4) Cyclin G-associated Kinase (GAK) (1) Cyclophilin (2) Discoidin Domain Receptor (2) Drug Metabolite (3) E3 Ligase Ligand-Linker Conjugates (1) EGFR (5) Ephrin Receptor (2) ERK (4) Farnesyl Transferase (1) Ferroptosis (9) FGFR (7) FLT3 (8) Glutathione S-transferase (1) HBV (1) HCV (1) HDAC (1) HIV (1) HSP (1) Interleukin Related (1) Isotope-Labeled Compounds (3) JNK (3) MAPKAPK2 (MK2) (1) MDM-2/p53 (2) MEK (9) Microtubule/Tubulin (1) Molecular Glues (3) mTOR (1) NF-κB (1) P-glycoprotein (1) p38 MAPK (5) PDGFR (10) PERK (2) Phosphatase (1) Phospholipase (1) PROTACs (2) Ras (16) Reactive Oxygen Species (2) RET (11) Ribosomal S6 Kinase (RSK) (1) ROS Kinase (1) SHP2 (1) Small Interfering RNA (siRNA) (3) Src (4) TAM Receptor (1) Tie (7) TNF Receptor (2) Tyrosinase (1) VEGFR (24)
By Research Areas:	Cancer (144) Cardiovascular Disease (1) Infection (3) Inflammation/Immunology (6) Metabolic Disease (2) Neurological Disease (7)
Click Chemistry:	Alkynes (1)
Oligonucleotides:	Pre-designed siRNA Sets (3) Antisense Oligonucleotides (2) siRNAs (3)

157

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Peptides

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Oligonucleotides

Targets Recommended: Raf

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-14177

Raf inhibitor 1 3 Publications Verification	Raf	Cancer
Raf inhibitor 1 is a potent *Raf* kinase inhibitor with K_is of 1 nM, 1 nM, and 0.3 nM for B-Raf ^WT, B-Raf ^V600E, and C-Raf, respectively.

HY-100510

RAF709 5+ Cited Publications	Raf	Cancer
RAF709 is a potent, selective, and efficacious *RAF* inhibitor with IC₅₀s of 0.4 nM and 0.5 nM for BRAF and CRAF, respectively . Antitumor efficacy .

HY-10248

RAF265 5+ Cited Publications CHIR-265	Raf VEGFR Autophagy Apoptosis	Cancer
RAF265 is a potent and orally active *RAF/VEGFR2* inhibitor.

HY-147268

Exarafenib RAF/KIN_2787	Raf p38 MAPK	Cancer
Exarafenib (RAF/KIN_2787) is an orally-available, selective pan-RAF inhibitor. Exarafenib is effective in RAF-dependent cancers, including all classes of BRAF alterations. Exarafenib suppresses MAPK signaling in RAF-dependent melanoma cell lines. Exarafenib has anticancer activity .

HY-109574

Raf inhibitor 2	Raf	Cancer
Raf inhibitor 2 is a potent raf kinase (IC₅₀<1.0 μM) inhibitor, compound 32, extracted from patent EP1003721B1. Raf inhibitor 2 can be used for cancer research .

HY-156554

Raf inhibitor 3	Raf	Cancer
Raf inhibitor 3 (Example 30) is a *Raf* inhibitor. Raf inhibitor 3 inhibits B-Raf and C-Raf with IC₅₀ values less than 15 nM. Raf inhibitor 3 can be used for research of cancers .

HY-14177A

Raf inhibitor 1 dihydrochloride	Raf	Cancer
B-Raf inhibitor 1 dihydrochloride is a potent *Raf* kinase inhibitor with K_is of 1 nM, 1 nM, and 0.3 nM for B-Raf ^WT, B-Raf ^V600E, and C-Raf, respectively.

HY-126298

RAF mutant-IN-1	Raf	Cancer
RAF mutant-IN-1 is a RAF kinase inhibitor, extracted from patent WO2019107987A1, with IC₅₀ values of 21 nM, 30 nM and 392 nM for C-RAF ^340D/Y341D, B-RAF ^V600E and B-RAF ^WT, respectively .

HY-144271

RAF-IN-1	Raf	Cancer
RAF-IN-1 is a potent b/cRAF inhibitor with an IC₅₀s of 3.8 nM, 36 nM, 29.4 nM for cRAF, bRAF ^wt, and bRAF ^V600E. RAF-IN-1 shows cell growth inhibition with GI₅₀s of 3.4 and 2.9 nM for H358 and A375 cell line bearing bRAF ^V600E mutation, respectively .

HY-RS11619

RAF1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
RAF1 Human Pre-designed siRNA Set A contains three designed siRNAs for RAF1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

RAF1 Human Pre-designed siRNA Set A RAF1 Human Pre-designed siRNA Set A

HY-RS11620

Raf1 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Raf1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Raf1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Raf1 Mouse Pre-designed siRNA Set A Raf1 Mouse Pre-designed siRNA Set A

HY-RS11621

Raf1 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Raf1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Raf1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Raf1 Rat Pre-designed siRNA Set A Raf1 Rat Pre-designed siRNA Set A

HY-164484

*IHMT-RAF-128*	Raf	Cancer
IHMT-RAF-128, a highly potent pan-RAF inhibitor. IHMT-RAF-128 shows potent antitumor efficacy in xenograft mouse tumor models without causing any apparent toxicities .

HY-157750

*MEK1/C-Raf-IN-1*	MEK Raf	Cancer
MEK1/C-Raf-IN-1 (Compound 14d) is a *MEK1/C-Raf* inhibitor with IC₅₀ values of 97 and 23 nM, respectively. MEK1/C-Raf-IN-1 has antitumor activity .

HY-146303

*C-RAF* kinase-IN-1**	Others	Cancer
C-RAF kinase-IN-1 (compound 1l) is a potent inhibitor of *C-RAF* kinase with an IC₅₀ of 0.193 μM. C-RAF kinase-IN-1 is a quinoline derivative. C-RAF kinase-IN-1 has the potential for the research of cancer diseases .

HY-138294

*RAS/RAS-RAF-IN-1* 1 Publications Verification	Ras Raf	Cancer
RAS/RAS-RAF-IN-1 is a potent RAS and *RAS-RAF* inhibitor. RAS/RAS-RAF-IN-1 has a K_D of 5.0 μΜ-15 μΜ for cyclophilin A (CYPA) binding affinity. RAS/RAS-RAF-IN-1 has antitumor activity .

HY-77113

*B-Raf* IN 11**	Raf	Cancer
B-Raf IN 11 (ZINC72115182) is a selective *B-Raf* ^V600E inhibitor (IC₅₀*=76 nM), shows selectivity for B-Raf* ^V600E over B-Raf ^WT with selectivity of 3.1-fold. B-Raf IN 11 can be used in colorectal cancer research

HY-120676

*B-Raf* IN 18**	Raf	Cancer
B-Raf IN 18 (compound 26) is a *B-Raf* inhibitor, with IC₅₀ of 3.8 nM. B-Raf IN 18 can be used in anti-cancer related research .

HY-142820

*B-Raf* IN 5**	Raf	Cancer
B-Raf IN 5 (compound 3b) is a potent inhibitor of protein kinase *B-Raf* with an IC₅₀ of 2.0 nM. B-Raf IN 5 is devoid of binding to the secondary target PXR and resists rapid metabolism. B-Raf IN 6 has the potential for the research of cancer disease .

HY-142830

*B-Raf* IN 6**	Raf	Cancer
B-Raf IN 6 (compound 2c) is a potent inhibitor of protein kinase *B-Raf* with an IC₅₀ of 1.7 nM. B-Raf IN 6 is devoid of binding to the secondary target PXR and resists rapid metabolism. B-Raf IN 6 has the potential for the research of cancer disease .

HY-18227

*B-Raf* IN 1**	Raf	Cancer
B-Raf IN 1 is a potent and selective *B-Raf* kinase inhibitor with an IC₅₀ of 24 nM.

HY-142452

*Pan-RAF* kinase inhibitor 1**	Raf	Cancer
Pan-RAF kinase inhibitor 1 is a potent inhibitor of *Pan-RAF* kinase*. Pan-RAF* kinase inhibitor 1 regulates MAPK signaling by inhibiting RAF kinase, thereby exerting an effect on the proliferation of RAS-mutant tumor cells. Pan-RAF kinase inhibitor 1 has the potential for the research of cancer diseases (extracted from patent WO2021110141A1, compound 16B) .

HY-147854

*B-Raf* IN 9**	Raf Apoptosis	Cancer
B-Raf IN 9 (compound 8b) is a potent *B-Raf* inhibitor, with an IC₅₀ of 24.79 nM. B-Raf IN 9 induces apoptosis and shows cell cycle arrest at G2/M phase. B-Raf IN 9 exhibits potent antitumor activity against human prostate cancer PC-3 cell line, with an IC₅₀ of 7.83 µM .

HY-153603

*B-Raf* IN 15**	Raf	Cancer
B-Raf IN 15 (Compound 7) is a BRAF inhibitor. B-Raf IN 15 inhibits BRAF WT and BRAF V600E with IC₅₀s of 2.0 and 0.8 μM. B-Raf IN 15 can be used for the research of cancer .

HY-156590

*B-Raf* IN 16**	Raf	Cancer
B-Raf IN 16 (Compound I) is a BRAF inhibitors that belongs a cyclic iminopyrimidine derivative. B-Raf IN 16 can be used for cancer research .

HY-145120

*B-Raf* IN 2**	Raf	Cancer
B-Raf IN 2 is a potent and selective BRAF inhibitor extracted from patent WO2021116055A1, compound Ia. B-Raf IN 2 can be used for the research of cancer .

HY-150250

*B-Raf* IN 13**	Raf	Cancer
B-Raf IN 13 is a BRAF inhibitor with an IC₅₀ of 3.55 nM in BRAF V600E enzyme assay. B-Raf IN 13 has anticaner effects (WO2020261156A1, Example 74) .

HY-111758

*PROTAC B-Raf* degrader 1**	PROTACs Raf	Cancer
PROTAC B-Raf degrader 1 (compound 2) is a proteolysis targeting chimera (PROTAC) for the degradation of *B-Raf* based on Cereblon ligand with anti-cancer activity .

HY-162873

*MEK/RAF-IN-1*	MEK Raf	Cancer
MEK/RAF-IN-1 (Compound 16b) is an inhibitor of both MEK and *RAF. It shows potent inhibition with IC₅₀* values of 28 nM for MEK1, and 3 nM each for BRAF and BRAFV600E. MEK/RAF-IN-1 demonstrates significant antitumor activity, effectively inhibiting cell proliferation in vitro against MIA PaCa-2 (G12C KRAS), HCT116 (G13D KRAS), and C26 (G12D KRAS) cells. Additionally, it inhibits tumor growth in xenograft mouse models of colorectal cancer .

HY-158027

*B-Raf* IN 17**	Raf VEGFR FGFR	Cancer
B-Raf IN 17 (Compound 8e) is a potent and orally active type II multi-kinase inhibitor. B-Raf IN 17 exhibits potent cellular-level suppression of BRAF_WT, VEGFR-2, and FGFR-1 in A375 cell line, with IC₅₀ values of 0.02, 0.18 and 1.65 μM, respectively. B-Raf IN 17 can be used for the research of cancer .

HY-15717

Kobe2602	Ras	Cancer
Kobe2602 is a *Ras-Raf* interaction** inhibitor. Kobe2602 inhibits the binding of H-Ras·GTP to c-Raf-1 RBD with a K_i of 149 μM. Kobe2602 has antitumor activity .

HY-164492

LSN3074753	Raf	Cancer
LSN3074753, an analog of LY3009120 (HY-12558), is a pan-RAF and *Raf* dimer inhibitor. LSN3074753 demonstrates activity against tumor cells with MAPK pathway activation driven by BRAF monomer or *RAF* dimers including BRAF- or KRAS-mutant colorectal cancer. LSN3074753 combined with Cetuximab (HY-P9905) shows additive and synergistic effects for colorectal cancer PDX models, particularly those with KRAS or BRAF mutation .

HY-147853

*B-Raf* IN 8**	Raf	Cancer
B-Raf IN 8 (compound 7g) is a potent *B-Raf* inhibitor, with an IC₅₀ of 70.65 nM. B-Raf IN 8 exhibits antitumor activity against hepatocellular carcinoma (HEPG-2), colon carcinoma (HCT-116), mammary gland (MCF-7) and human prostate cancer (PC-3) cells, with IC₅₀ values of 9.78, 13.78, 18.52 and 29.85 µM .

HY-147852

*B-Raf* IN 7**	Raf	Cancer
B-Raf IN 7 (compound 6a) is a potent *B-Raf* inhibitor, with an IC₅₀ of 110.23 nM. B-Raf IN 7 exhibits antitumor activity against colon carcinoma (HCT-116), mammary gland (MCF-7), hepatocellular carcinoma (HEPG-2), human cervical carcinoma (Hela) and human prostate cancer (PC-3) cells, with IC₅₀ values of 7.50, 9.87, 10.57, 11.63 and 12.83 µM .

HY-153914

*B-Raf* IN 14**	Raf	Cancer
B-Raf IN 14 (Comp 25) is a BRAF inhibitor with IC₅₀ value of 11.08 μM, which can be used in cancer-related research .

HY-136420

SJF-0628	PROTACs Raf	Cancer
SJF-0628 (compound 512) is a PROTAC *RAF* degrader. SJF-0628 induces targeted degradation of BRAF mutants (DC₅₀: 5.4 nM, 4.64 nM, 15.5 nM, 2.11 nM, 63.9 nM for BRAF V600E, V600K, G464V, G469A, K601E respectively). SJF-0628 has anti-tumor activity. SJF-0628 can be used for research of disorders that result from aggregation or accumulation of RAF, or the constitutive activation of RAF .

HY-148059

Uplarafenib B-RAF IN 10	Raf	Cancer
Uplarafenib (B-Raf IN 10) (Compound C09) is a BRAF inhibitor with an IC₅₀ between 50 and 100 nM. Uplarafenib shows antitumor activity .

HY-18957B

Lifirafenib maleate BGB-283 maleate	EGFR Raf	Others Cancer
Lifirafenib (BGB-283) maleate is a novel and potent *Raf* Kinase and EGFR inhibitor with IC₅₀ values of 23 and 29 nM for recombinant BRaf ^V600E and EGFR, respectively .

HY-14979A

ML786 dihydrochloride	Raf Bcr-Abl Discoidin Domain Receptor VEGFR RET Ephrin Receptor	Cancer
ML786 dihydrochloride is a potent and orally bioavailable *Raf* inhibitor, with IC₅₀s of 2.1, 4.2, and 2.5 nM for ^V600EΔB-Raf, wt B-Raf, and *C-Raf, respectively. ML786 dihydrochloride also inhibits Abl-1, DDR2, EPHA2, KDR, and RET* (IC₅₀=<0.5, 7.0, 11, 6.2, 0.8 nM). ML786 dihydrochloride can be used for the research of cancers .

HY-157740

XSJ-10	HDAC	Cancer
XSJ-10 is a HDAC inhibitor containing a RAS/RAF protein interfering unit, with IC_{50_s} of 0.05 and 0.04 μM in PANC-1 cells and HT-29 cells. XSJ-10 can effectively induce the apoptosis of cancer cells and suppress the tumor by strongly inhibiting the RAS-RAF-MEK-ERK signaling pathway and the acetylation level of HDAC3 .

HY-108887

Anticancer agent 124	Raf	Cancer
Anticancer agent 124 is an orally active, highly selective and potent pan *RAF* inhibitor. Anticancer agent 124 inhibits MAPK signalling in BRAF V600E, NRAS and KRAS mutant tumor cells .

HY-P10438

Tat-braftide	Raf	Cancer
Tat-braftide is a peptide inhibitor designed to block the dimerization of BRAF, thereby inhibiting its kinase activity. The destruction of BRAF dimer by Tat-braftide makes BRAF protein more susceptible to proteasome degradation, directly inhibits the activity of BRAF kinase, and reduces the activation of MAPK signaling pathway. Tat-braftide can be used for the role of *RAF* kinase in MAPK signaling pathway and for the study of BRAF mutant cancers .

HY-169212

I194496	Others	Cancer
I194496 is a potent cystathionine γ-lyase (CSE) inhibitor, with an IC₅₀ of 0.79 mM. I194496 can inhibit the growth of human TNBC cells via the dual targeting PI3K/Akt and Ras/Raf/ERK pathway and suppress the metastasis of human TNBC cells via down-regulating Anxa2/STAT3 and VEGF/FAK/Paxillin signaling pathways .

HY-109080

Belvarafenib 3 Publications Verification HM95573; GDC-5573; RG6185	Raf	Cancer
Belvarafenib (HM95573) is a potent and pan *RAF* (Rapidly Accelerated Fibrosarcoma) inhibitor, with IC₅₀s of 56 nM, 7 nM and 5 nM for B-RAF, B-RAF ^v600E and C-RAF respectively .

HY-14660A

Dabrafenib Mesylate 50+ Cited Publications GSK2118436 Mesylate; GSK 2118436B	Raf	Cancer
Dabrafenib Mesylate is a potent and selective Raf kinase inhibitor with IC₅₀s of 0.6 and 5.0 nM for Raf ^V600E and c-Raf, respectively.

HY-14660

Dabrafenib 50+ Cited Publications GSK2118436A; GSK2118436	Raf	Cancer
Dabrafenib (GSK2118436A) is an ATP-competitive inhibitor of *Raf* with IC₅₀s of 5 nM and 0.6 nM for *C-Raf* and *B-Raf* ^V600E**, respectively .

HY-11004

AZ 628 5+ Cited Publications	Raf Apoptosis	Cancer
AZ 628 is a *pan-Raf* kinase inhibitor with IC₅₀s of 105, 34 and 29 nM for *B-Raf, B-RafV600E, and c-Raf-1*, respectively.

HY-10201S1

Sorafenib-d4 Bay 43-9006-d₄	Raf VEGFR FLT3 Ferroptosis Autophagy Apoptosis	Cancer
Sorafenib-d₄ is the deuterium labeled Sorafenib. Sorafenib is a multikinase inhibitor IC50s of 6 nM, 20 nM, and 22 nM for Raf-1, B-Raf, and VEGFR-3, respectively.

HY-10966

SB-590885 5 Publications Verification	Raf	Cancer
SB-590885 is a potent B-Raf* inhibitor* with K_i of 0.16 nM, and has 11-fold greater selectivity for B-Raf over c-Raf, without inhibition to other human kinases.

HY-P1039

R18 PHCVPRDLSWLDLEANMCLP	Raf	Cancer
R18 is a peptide antagonists of 14-3-3, with a K_D of 70-90 nM. R18 efficiently blocks the binding of 14-3-3 to the kinase Raf-1, a physiological ligand of 14-3-3, and effectively abolished the protective role of 14-3-3 against phosphatase-induced inactivation of Raf-1 .

Cat. No.	Product Name

HY-L196

Protein Kinase Compound Library

2,930 compounds

Protein Kinases (PTKs) are a class of phosphotransferases that phosphorylate proteins. Protein kinases participate in many signal transduction pathways including those involved with growth, differentiation, and cell division. Protein kinase not only plays an important role in the process of cell activation, but also its abnormal expression is closely related to the pathogenesis of many diseases. So far, the protein kinase family has become one of the most important drug targets. The most common drug targets include ALK, B-Raf, BCR-Abl, EGFR, and VEGFR.

MCE designs a unique collection of 2,930 bioactive compounds targeting protein kinases, which is an important tool for the development of drug targeting protein kinases.

HY-L010

MAPK Compound Library

569 compounds

MAPK families play an important role in complex cellular programs like proliferation, differentiation, development, transformation, and apoptosis. In mammalian cells, four MAPK families have been clearly characterized: ERK1/2, C-Jun N-terminal kinse/stress-activated protein kinase (JNK/SAPK) , p38 kinase and ERK5. They respond to different signals. Each MAPK-related cascade consists of three enzymes that are activated in series: a MAPK kinase kinase (MAPKKK), a MAPK kinase (MAPKK) and a MAP kinase (MAPK). MAPK signaling pathways has been implicated in the development of many human diseases including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS) and various types of cancers.

MCE designs a unique collection of 569 MAPK signaling pathway inhibitors that act as a useful tool for MAPK-related drug screening and disease research.

HY-L101

Anti-Liver Cancer Compound Library

1,969 compounds

Liver cancer is one of the leading malignancies which occupies the second position in cancer deaths worldwide, becoming serious threat to human health. Hepatocellular carcinoma (HCC), also known as hepatoma is the most common type accounting for approximately 90% of all liver cancers.

Current evidence indicates that during hepatocarcinogenesis, two main pathogenic mechanisms prevail: (1) cirrhosis associated with hepatic regeneration after tissue damage caused by hepatitis infection, toxins or metabolic influences, and (2) mutations occurring in single or multiple oncogenes or tumor suppressor genes. Both mechanisms have been linked with alterations in several important cellular signaling pathways. These include the RAF/MEK/ERK pathway, PI3K/AKT/mTOR pathway, WNT/b-catenin pathway, insulin-like growth factor pathway, c-MET/HGFR pathway , etc.

MCE offers a unique collection of 1,969 compounds with identified and potential anti-liver cancer activity. MCE anti-liver cancer compound library is a useful tool for anti-liver cancer drugs screening and other related research.

Cat. No.	Product Name	Type

HY-114491

Rineterkib

Fluorescent Dyes/Probes

Rineterkib (compound B) is an orally available ERK1 and ERK2 inhibitor in the treatment of a proliferative disease characterized by activating mutations in the MAPK pathway. The activity is particularly related to the treatment of KRAS-mutant NSCLC, BRAF-mutant NSCLC, KRAS-mutant pancreatic cancer, KRAS-mutant colorectal cancer (CRC) and KRAS-mutant ovarian cancer. Rineterkib hydrochloride can also inhibit RAF .

Cat. No.	Product Name	Target	Research Area

HY-P1039A

R18 TFA PHCVPRDLSWLDLEANMCLP TFA	Raf	Cancer
R18 TFA is a peptide antagonists of 14-3-3, with a K_D of 70-90 nM. R18 efficiently blocks the binding of 14-3-3 to the kinase Raf-1, a physiological ligand of 14-3-3, and effectively abolished the protective role of 14-3-3 against phosphatase-induced inactivation of Raf-1 .

HY-P10438

Tat-braftide	Raf	Cancer
Tat-braftide is a peptide inhibitor designed to block the dimerization of BRAF, thereby inhibiting its kinase activity. The destruction of BRAF dimer by Tat-braftide makes BRAF protein more susceptible to proteasome degradation, directly inhibits the activity of BRAF kinase, and reduces the activation of MAPK signaling pathway. Tat-braftide can be used for the role of *RAF* kinase in MAPK signaling pathway and for the study of BRAF mutant cancers .

HY-P1039

R18 PHCVPRDLSWLDLEANMCLP	Raf	Cancer
R18 is a peptide antagonists of 14-3-3, with a K_D of 70-90 nM. R18 efficiently blocks the binding of 14-3-3 to the kinase Raf-1, a physiological ligand of 14-3-3, and effectively abolished the protective role of 14-3-3 against phosphatase-induced inactivation of Raf-1 .

HY-P10051

Cyclorasin 9A5	Ras Raf	Cancer
Cyclorasin 9A5 is an 11-residue cell-permeable cyclic peptide that orthosterically inhibits the *Ras-Raf* protein interaction with an IC₅₀ of 120 nM .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N3468

Isomerazin	Structural Classification other families Source classification Coumarins Phenylpropanoids Plants	Cholinesterase (ChE)
Isomerazin is a coumarin isolated from Poncirus trifoliate Raf., and shows cholinesterase inhibition .

HY-N6796

Manumycin A	Infection Structural Classification Microorganisms Classification of Application Fields Antibiotics Source classification Disease Research Anticancer Disease Research Fields Other Antibiotics	Farnesyl Transferase Ras Apoptosis Phospholipase TNF Receptor Atg8/LC3
Manumycin A is a polyketide antibiotic and an inhibitor of thioredoxin reductase 1 (TrxR-1). Manumycin A can inhibit the growth of breast cancer cells and exert its anti-tumor activity through LC3. Manumycin A can downregulate the release of pro-inflammatory cytokines in human monocytes stimulated by TNF α, and has potential anti-inflammatory activity. Manumycin A can inhibit the *Ras/Raf/ERK1/2* signaling and hnRNP H1 in castration resistant prostate cancer cells to suppress exosome biogenesis and secretion .

HY-N10503

Norartocarpetin	Structural Classification Flavonoids Flavones Plants Moraceae	Tyrosinase Ras Raf MAPKAPK2 (MK2) Apoptosis
Norartocarpetin is a tyrosinase inhibitor. Norartocarpetin has strong tyrosinase inhibitory activity with an IC₅₀ value of 0.47 μM. Norartocarpetin as an antibrowning agent can be used for the research of food systems. Norartocarpetin also has a significant anticancer activity in lung carcinoma cells (NCI-H460) with an IC₅₀ value of 22 μM. Norartocarpetin has antiproliferative effects are mediated via targeting Ras/Raf/MAPK signalling pathway, mitochondrial mediated apoptosis, S-phase cell cycle arrest and suppression of cell migration and invasion in human lung carcinoma cells .

HY-N0226A

Epiberberine chloride 4 Publications Verification	Alkaloids Structural Classification Neurological Disease Classification of Application Fields Coptis chinensis Franch. Ranunculaceae Source classification Metabolic Disease Plants Isoquinoline Alkaloids Disease Research Fields	Cholinesterase (ChE) Beta-secretase Reactive Oxygen Species
Epiberberine chloride is an alkaloid isolated from Coptis chinensis, acts as a potent AChE and BChE inhibitor, and a non-competitive BACE1 inhibitor, with IC₅₀s of 1.07, 6.03 and 8.55 μM, respectively. Epiberberine chloride has antioxidant activity, with peroxynitrite ONOO ^- scavenging effect (IC₅₀, 16.83 μM), and may protect against Alzheimer disease . Epiberberine chloride inhibits the early stage of differentiation of 3T3-L1 preadipocytes, downregulates the Raf/MEK1/2/ERK1/2 and AMPKα/Akt pathways . Epiberberine has the potential effect in the research of diabetic disease .

HY-18957B

Lifirafenib maleate BGB-283 maleate	Classification of Application Fields Disease Research Fields Cancer	EGFR Raf
Lifirafenib (BGB-283) maleate is a novel and potent *Raf* Kinase and EGFR inhibitor with IC₅₀ values of 23 and 29 nM for recombinant BRaf ^V600E and EGFR, respectively .

HY-N3468R

Isomerazin (Standard)	Structural Classification other families Source classification Coumarins Phenylpropanoids Plants	Cholinesterase (ChE)
Isomerazin (Standard) is the analytical standard of Isomerazin. This product is intended for research and analytical applications. Isomerazin is a coumarin isolated from Poncirus trifoliate Raf., and shows cholinesterase inhibition .

HY-113632

Debromohymenialdisine 10Z-Debromohymenialdisine	Structural Classification Natural Products Classification of Application Fields Marine natural products Sponge Disease Research Fields Cancer	Raf MEK
Debromohymenialdisine (10Z-Debromohymenialdisine) is a pyrrole alkaloid. Debromohymenialdisine has moderate inhibitory activity with an IC₅₀ value of 881 nM in the initial *Raf/MEK-1/MAPK* signaling cascade assay. Debromohymenialdisine can be used for the research of proliferation and differentiation .

HY-W065835

2-Bromoaldisine	Structural Classification Alkaloids Pyrrole Alkaloids Marine natural products Source classification	HIV
2-Bromoaldisine is a pyrrole alkaloid that can be isolated from the Red Sea: marine sponge Stylissa carter. 2-Bromoaldisine inhibits HIV-1 vector infection. 2-Bromoaldisine inhibits *Raf/MEK/MAPK* pathway .

HY-N3634

Corylifol C	Structural Classification Leguminosae Source classification Phenols Polyphenols Psoralea corylifolia L. Plants	EGFR TAM Receptor Tie
Corylifol C is a potent protein kinase inhibitor with IC₅₀ valueS of 8.7, 3.0, 2.1, 6.4, 4.5, 6.2, 2.3, 1.2, 5.1 μg/ml for ARK5, Aurora-A, Aurora-B, AXL, B-RAF-VE, CDK4/CycD1, TIE2, EGF-R, EPHB4, respectively .

HY-N0226

Epiberberine	Alkaloids Source classification Ranunculaceae Coptis chinensis Franch. Plants Isoquinoline Alkaloids	Cholinesterase (ChE) Beta-secretase
Epiberberine is an alkaloid isolated from Coptis chinensis, acts as a potent AChE and BChE inhibitor, and a non-competitive BACE1 inhibitor, with IC₅₀s of 1.07, 6.03 and 8.55 μM, respectively. Epiberberine has antioxidant activity, with peroxynitrite ONOO ^- scavenging effect (IC₅₀, 16.83 μM), and can be used for the research of Alzheimer disease . Epiberberine inhibits the early stage of differentiation of 3T3-L1 preadipocytes, downregulates the Raf/MEK1/2/ERK1/2 and AMPKα/Akt pathways . Epiberberinecan be used for the research of diabetic disease .

Species:	Human (3)
Tag:	His (2) GST (3)
Source:	Sf9 insect cells (3)

Cat. No.	Compare	Product Name	Species	Source

HY-P702733

	RAF1 Protein, Human (Y340D,Y341D, sf9, His, GST) RAF1; RAF-1 proto-oncogene, serine/threonine kinase; NS5; CRAF; RAF-1; c-RAF; CMD1NN; RAF proto-oncogene serine/threonine-protein kinase; C-RAF proto-oncogene, serine/threonine kinase; Oncogene RAF1; proto-oncogene c-RAF; RAF proto-oncogene serine/threonine protein kinase; v-RAF-1 murine leukemia viral oncogene homolog 1; v-RAF-1 murine leukemia viral oncogene-like protein 1; EC 2.7.11.1	Human	Sf9 insect cells

HY-P702921

	BRAF Protein, Human (sf9, GST, His) BRAF1; RAFB; Proto-oncogene B-RAF; p94; v-RAF murine sarcoma viral oncogene homolog B1	Human	Sf9 insect cells
	BRAF Protein, Human (sf9, GST, His) is the recombinant human-derived BRAF, expressed by Sf9 insect cells .

HY-P702903

	TNK1 Protein, Human (sf9, GST) CD38 Negative Kinase 1; Tyrosine Kinase Non Receptor 1; Mitogen-Activated Protein Kinase 1; MAPK1; CD36 Molecule; CD36; RAF1	Human	Sf9 insect cells
	TNK1 Protein, Human (sf9, GST) is the recombinant human-derived TNK1, expressed by Sf9 insect cells , with GST labeled tag. ,

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-10201S

Sorafenib-d3
Sorafenib-d₃ (Donafenib), a deuterated compound of Sorafenib, is the first deuterium-generation tumor suppressor small molecule. Sorafenib is a multikinase inhibitor IC₅₀s of 6 nM, 20 nM, and 22 nM for Raf-1, B-Raf, and VEGFR-3, respectively .

HY-10201S2

Sorafenib-13C,d3

1 Publications Verification

Sorafenib- ¹³C,d₃ is the ¹³C- and deuterium labeled Sorafenib. Sorafenib (Bay 43-9006) is a potent and orally active Raf inhibitor with IC50s of 6 nM and 20 nM for Raf-1 and B-Raf, respectively. Sorafenib is a multikinase inhibitor with IC50s of 90 nM, 15 nM, 20 nM, 57 nM and 58 nM for VEGFR2, VEGFR3, PDGFRβ, FLT3 and c-Kit, respectively. Sorafenib induces autophagy and apoptosis. Sorafenib has anti-tumor activity. Sorafenib is a ferroptosis activator[1].

HY-10201S1

Sorafenib-d4
Sorafenib-d₄ is the deuterium labeled Sorafenib. Sorafenib is a multikinase inhibitor IC50s of 6 nM, 20 nM, and 22 nM for Raf-1, B-Raf, and VEGFR-3, respectively.

HY-14660S

Dabrafenib-d9
Dabrafenib-d₉ is the deuterium labeled Dabrafenib. Dabrafenib (GSK2118436A) is an ATP-competitive inhibitor of Raf with IC50s of 5 nM and 0.6 nM for C-Raf and B-RafV600E, respectively[4].

HY-12057S

Vemurafenib-d5
Vemurafenib-d₅ is the deuterium labeled Vemurafenib. Vemurafenib (PLX4032) is a first-in-class, selective, potent inhibitor of B-RAF kinase, with IC50s of 31 and 48 nM for RAFV600E and c-RAF-1, respectively[1][4]. Vemurafenib induces cell autophagy[5].

HY-12057S1

Vemurafenib-d7
Vemurafenib-d₇ is deuterium labeled Vemurafenib. Vemurafenib (PLX4032) is a first-in-class, selective, potent inhibitor of B-RAF kinase, with IC50s of 31 and 48 nM for RAFV600E and c-RAF-1, respectively[1][4]. Vemurafenib induces cell autophagy[5].

HY-10331S1

Regorafenib-13C,d3
Regorafenib- ¹³C,d₃ is the ¹³C- and deuterium labeled Regorafenib. Regorafenib (BAY 73-4506) is a multi-targeted receptor tyrosine kinase inhibitor with IC50s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively.

HY-I0678S1

Regorafénib N-oxyde (M2)-13C,d3
Regorafénib N-oxyde (M2)- ¹³C,d₃ is the ¹³C- and deuterium labeled Regorafénib N-oxyde (M2). Regorafénib N-oxyde M2 is an active metabolite of Regorafenib. Regorafenib is a multi-target inhibitor for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1 with IC50s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM, respectively.

HY-I0678S

Regorafénib N-oxyde-d3 (M2)
Regorafénib N-oxyde-d₃(M2) is the deuterium labeled Regorafénib N-oxyde M2[1]. Regorafénib N-oxyde M2 is an active metabolite of Regorafenib. Regorafenib is a multi-target inhibitor for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1 with IC50s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM, respectively[2].

HY-51424S

PLX-4720-d7
PLX-4720-d₇ is the deuterium labeled PLX-4720. PLX-4720 is a potent and selective inhibitor of B-RafV600E with an IC50 of 13 nM in a cell-free assay, equally potent to c-Raf-1(Y340D and Y341D mutations), and 10-fold selectivity for B-RafV600E than wild-type B-Raf[1][2].

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P80880

	Raf1 Antibody RAF1; RAF; RAF proto-oncogene serine/threonine-protein kinase; Proto-oncogene c-RAF; cRAF; RAF-1	WB, ICC/IF	Human, Mouse, Rat
	Raf1 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 73 kDa, targeting to Raf1. It can be used for WB,ICC/IF assays with tag free, in the background of Human, Mouse, Rat.

HY-P80018

	*A-RAF* Antibody**	WB, ICC/IF, IHC-P, FC	Human, Mouse
	A-RAF Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 68 kDa, targeting to A-RAF. It can be used for WB,ICC/IF,IHC-P,FC assays with tag free, in the background of Human, Mouse.

HY-P80036

	*B-Raf* Antibody**	WB, IHC-P, ICC/IF	Human, Mouse, Rat
	B-Raf Antibody is a non-conjugated and Mouse origined monoclonal antibody about 84 kDa, targeting to B-Raf. It can be used for WB,IHC-P,ICC assays with tag free, in the background of Human, Mouse, Rat.

HY-P80572

	BRAF Antibody BRAF; BRAF1; RAFB1; Serine/threonine-protein kinase B-RAF; Proto-oncogene B-RAF; p94; v-RAF murine sarcoma viral oncogene homolog B1	WB	Human, Mouse, Rat
	BRAF Antibody is a non-conjugated and Mouse origined monoclonal antibody about 84 kDa, targeting to BRAF (4E1). It can be used for WB assays with tag free, in the background of Human, Mouse.

HY-P80794

	Phospho-BRAF (Thr401) Antibody BRAF; BRAF1; RAFB1; Serine/threonine-protein kinase B-RAF; Proto-oncogene B-RAF; p94; v-RAF murine sarcoma viral oncogene homolog B1	WB, IP	Human, Mouse, Rat
	Phospho-BRAF (Thr401) Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 84 kDa, targeting to Phospho-BRAF (Thr401). It can be used for WB,IP assays with tag free, in the background of Human, Mouse, Rat.

HY-P82124

	RKIP Antibody (YA1869) PEBP1; PBP; PEBP; Phosphatidylethanolamine-binding protein 1; PEBP-1; HCNPpp; Neuropolypeptide h3; Prostatic-binding protein; RAF kinase inhibitor protein; RKIP	WB, IHC-P, IP	Human, Mouse, Rat
	RKIP Antibody (YA1869) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1869), targeting RKIP, with a predicted molecular weight of 21 kDa (observed band size: 21 kDa). RKIP Antibody (YA1869) can be used for WB, IHC-P, IP experiment in human, mouse, rat background.

HY-P82928

	*A RAF* Antibody (YA2673)** ARAF; ARAF1; PKS; PKS2; Serine/threonine-protein kinase A-RAF; Proto-oncogene A-RAF; Proto-oncogene A-RAF-1; Proto-oncogene Pks	WB, IHC-P	Human
	A RAF Antibody (YA2673) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA2673), targeting A RAF, with a predicted molecular weight of 68 kDa (observed band size: 68 kDa). A RAF Antibody (YA2673) can be used for WB, IHC-P experiment in human background.